Drug Trial Radar · NCT07026279
A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
67
Planned (sponsor's estimate)
Start
Aug 18, 2025
Primary completion
Jul 2029
Study completion Jul 2029
Sponsor
- Lead sponsor
- Amplia Therapeutics LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jun 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is testing narmafotinib, a type of drug called a focal adhesion kinase (FAK) inhibitor, when it is given in combination with 4 chemotherapy drugs in a regimen called FOLFIRINOX, to patients who have pancreatic cancer which has metastasised (spread). The study is being run in 2 parts. Part A will test increasing dose levels of narmafotinib in at least 3 people per dose at up to 4 dose levels to assess safety. Part B will test 2 of the dose levels from Part A in 20 people per dose, to select the best dose to take forward into future studies. Participants will take narmafotinib as oral capsules every day. They will also receive mFOLFIRINOX chemotherapy on Day 1 and and Day 15 of 28-day cycles.
Conditions
- Pancreatic Cancer Metastatic
Interventions
narmafotinib ascending dosesDrug
once daily capsules
narmafotinib dose comparisonDrug
once daily capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-Emergent Adverse Events (TEAEs) from Baseline to End of StudyTime frame: From first dose of study drug to end of study, an expected average of 6 months
- Part B: identification of optimal dose of narmafotinibTime frame: From first dose of study drug to end of study, an expected average of 6 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
GenesisCare
St Leonards, New South Wales, Australia
Epworth Healthcare
Richmond, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.